This study is for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose disease has returned after treatment or has not responded to treatment, and who have previously received a Bruton tyrosine kinase (BTK) inhibitor.

This study is testing an investigational drug called BGB-16673. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA).

This is a randomized study, which means participants are assigned by chance (like flipping a coin) to receive either BGB-16673 or pirtobrutinib.The primary purpose of this study is to compare the safety and effectiveness of BGB-16673 with pirtobrutinib in patients with relapsed or refractory CLL or SLL.The study drugs are taken by mouth. Participants will attend regular study visits for health assessments, laboratory tests, and disease evaluations and will remain in the study until their disease worsens, they experience unacceptable side effects, choose to leave the study, or the study ends.

This study is to compare the usual treatment (radiation plus temozolomide alone) to using the study treatment (usual treatment plus the study drug, vorasidenib). The addition of the study drug, vorasidenib, to the usual treatment could shrink or stabilize your cancer. The study drug is FDA (Food and Drug Administration approved. The study drug will be given orally. The study will randomize (the computer will pick the group that the participant will be enrolled in) participant to Group 1 or Group 2. Participants can expect to be on the trial for 10 years or more. There will 4 participants enrolled locally.

The study will examine the effects of a 10-week resistance training program, with or without creatine monohydrate supplementation, on changes in body composition, physical function, cancer-related fatigue, quality of life, and symptom burden in head and neck cancer (HNC) survivors. All participants will undergo screening that includes completion of questionnaires, exercise testing and physical function assessments before and after the treatment period as well as at a 10-week follow up evaluation. We hypothesize that group that completes resistance training with creatine monohydrate supplementation will achieve greater improvements in body composition, physical function, cancer-related fatigue, quality of life, and symptom burden when compared to the group that completes resistance training alone.

This study is for patients that have been diagnosed with metastatic or advanced solid tumors. The study is testing an investigational drug called JZP898. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). The primary purpose of this study is to characterize the safety and tolerability profile of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab. The drug is given to participants by infusion. The length of your participation in this study may vary depending on the number of treatment cycles you receive. This will depend on whether there are any changes in your health during the study and whether the study doctor feels you should continue receiving the study drug.

Patients are matched with this clinical trial based on their biomarker test results in the myeloMATCH study. This treatment trial is for adults (ages 18-59) with high-risk AML who have not started treatment yet. Doctors consider AML high risk if it has certain biomarkers that can make it harder to treat. Treatment plans for AML often involve several phases of treatment. The first phase aims to get rid of as many leukemia cells as possible. It helps make it easier for further treatment to keep the cancer under control. Usually, the first treatment patients receive for AML is a combination of 2 chemotherapy drugs, daunorubicin and cytarabine. The purpose of this study is to learn if other options for first treatment may work better for people with high-risk AML. The study doctors will test 4 new treatments and compare them to the usual chemotherapy. This is important because knowing AML is high-risk gives doctors more information about the cancer and how to treat it. People with high-risk AML may benefit from a different approach to treatment. Improving options for people in the first phase of treatment could make further phases of treatment more successful.

This study is recruiting pediatric patients who have been diagnosed with osteosarcoma. Osteosarcoma is the most common primary bone malignancy of childhood and adolescence. The goal of the study is to determine the feasibility of adding cabozantinib to standard MAP (high dose methotrexate, doxorubicin, and cisplatin) chemotherapy in patients with newly diagnosed metastatic osteosarcoma with a resectable primary tumor and to compare the effects, good and/or bad, of cabozantinib in combination with MAP versus MAP alone on people with newly diagnosed OST to find out which is better. Common side effects of chemotherapy include nausea, vomiting, hair loss, and fatigue (tiredness). Participants will receive the medications through an IV in their arm and PO. Study participation is expected to last up to 16 months.

This study is for people who have a type of breast cancer that has spread to other parts of the body. Their cancer is hormone receptor (HR) positive and HER2 negative. The study looks at two cancer medicines, called palbociclib and ribociclib. These medicines are a type of targeted therapy. They are taken with standard hormone treatment. The goal of the study is to see how different starting doses of these medicines work in patients age 65 and older.
Participants are placed into one of two groups by chance:
Standard Dose Group: Patients start with the full dose approved by the FDA. If they have side effects, the dose is lowered.
Lower Dose Group: Patients start with a lower dose. The dose may be raised if they do not have strong side effects.

This study is testing a drug called silmitasertib to see if it is safe and works well when used with chemotherapy in children and young adults whose solid tumors have come back or didn't respond to treatment. In the first part of the study (Phase I), doctors will check how safe the drug is and what side effects it may cause. They will use a dose that is already recommended for adults and may try a slightly higher dose. Patients will take silmitasertib twice a day for 21 days along with chemotherapy. Doctors will then see if this treatment plan is safe and doable. In the second part (Phase II), the study will focus on two types of cancer: neuroblastoma and Ewing sarcoma. It will test how well silmitasertib works with chemotherapy for these cancers. The main goal is to see how many patients respond to the treatment. Other goals include seeing how long patients live without their cancer getting worse and how long they live overall. The study will include up to 104 patients across the country, including 2 at MUSC. The main risk is side effects. The most common ones expected are stomach problems, tiredness, low red blood cell count (anemia), and loss of appetite. There is no direct benefit for patients who join this study.

This study is for people with advanced non-small cell lung cancer (NSCLC) who have a KRAS G12C gene mutation. The study is testing a drug called BBO-8520. This drug is investigational, which means it has not been approved by the U.S. Food and Drug Administration (FDA). The drug will be tested by itself or together with another drug called pembrolizumab (also called "pembro"). People who have not taken a KRAS G12C inhibitor before and are in the Dose Expansion part of the study (Phase 1b) will be randomly assigned (like flipping a coin) to get one of two doses chosen by the study review committee (SRC). These doses are based on information from the earlier Dose Escalation part (Phase 1a). People who have taken a KRAS G12C inhibitor before may also be randomly assigned to one of two doses, but only after a first group of participants gets a set dose recommended by the SRC.

During the study, all participants will take BBO-8520 by mouth once or twice a day. If you are getting BBO-8520 with pembrolizumab, you will get pembrolizumab every 21 days. Pembrolizumab will be given through an IV about 30 minutes after you take BBO-8520. Pembrolizumab will continue until your cancer gets worse, you have side effects that are too severe, you choose to stop, or for up to 24 months—whichever happens first.
The whole study is expected to last about 5 years if the cancer does not get worse.

This study is for patients diagnosed with early-stage melanoma and are the age of 75 or older. The usual approach for patients who are not in a study is treatment with two surgical procedures, a wide local excision (WLE) plus a sentinel lymph node (SLN) biopsy, followed by immunotherapy. The purpose of this study is to find if performing the WLE alone is just as effective as the usual approach and if it leads to improvements in patients' overall well-being.

A wide local excision (A wide local excision (WLE) is a surgical procedure performed to cut out an abnormal lesion and some surrounding normal tissue; this is sometimes followed by a sentinel lymph node (SLN) biopsy, in which lymph nodes that cancer cells could spread to are removed as well. Immunotherapy is a type of cancer treatment that uses your body's immune system to identify and attack cancer cells.

Patients may participate in this study for up to 5 years. Procedures include a surgical biopsy, surveys, and regular visits with your doctor including follow-up study visits or phone calls every 6 months. There will be about 428 people taking part in this study, approximately 39 participants will be enrolled at MUSC.

Risks include infection, scarring, and bleeding. Participants may or may not receive a direct benefit from participating in this trial, however, information learned from the trial may help other people in the future.